.

Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar

LAUR Repository

Show simple item record

dc.contributor.author Mansour, Hanine
dc.contributor.author Al-Shaer, Mohammad H.
dc.contributor.author Elewa, Hazem
dc.contributor.author Salameh, Pascale
dc.contributor.author Iqbal, Fatima
dc.date.accessioned 2017-12-13T12:49:12Z
dc.date.available 2017-12-13T12:49:12Z
dc.date.copyright 2017 en_US
dc.identifier.issn 1471-2334 en_US
dc.identifier.uri http://hdl.handle.net/10725/6783
dc.description.abstract Background: Tuberculosis is considered the second most common cause of death due to infectious agent. The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC). To date, no studies have compared both regimens in Qatar. We aim to evaluate the safety and effectiveness of FDC and ST regimen for treating PTB, in addition to comparing safety and efficacy of FDC and ST regimens in patients with diabetes treated for TB. Methods: A retrospective observational study was conducted in two general hospitals in Qatar. Patients diagnosed with PTB received anti-tuberculosis medications (either as FDC or ST) administered by the nurse. Sputum smears were tested weekly. We assessed the time to negative sputum smear and incidence of adverse events among FDC and ST groups. Results: The study included 148 patients. FDC was used in 90 patients (61%). Effectiveness was not different between FDC and ST regimens as shown by mean time to sputum conversion (29.9 ± 18.3 vs. 35.6 ± 23 days, p = 0.12). Similarly, there was no difference in the incidence of adverse events, except for visual one that was higher in ST group. Among the 33 diabetic patients, 19 received the FDC and had faster sputum conversion compared to those who received ST (31 ± 12 vs. 49.4 ± 30.9 days, p = 0.05). Overall, diabetic patients needed longer time for sputum conversion and had more hepatotoxic and gastric adverse events compared to non-diabetics. Conclusion: ST group had higher visual side effects compared to FDC. FDC may be more effective in diabetic patients; however, further studies are required to confirm such finding. en_US
dc.language.iso en en_US
dc.title Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 201205628 en_US
dc.author.department Pharmacy Practice Department en_US
dc.description.embargo N/A en_US
dc.relation.journal BMC Infectious Diseases en_US
dc.journal.volume 17 en_US
dc.journal.issue 118 en_US
dc.keywords Pulmonary tuberculosis en_US
dc.keywords Fixed-dose en_US
dc.keywords Separate tablets en_US
dc.keywords Effectiveness en_US
dc.keywords Safety en_US
dc.identifier.doi http://dx.doi.org/10.1186/s12879-017-2231-1 en_US
dc.identifier.ctation Al-Shaer, M. H., Mansour, H., Elewa, H., Salameh, P., & Iqbal, F. (2017). Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC infectious diseases, 17(1), 118. en_US
dc.author.email hanine.mansour@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-017-2231-1?site=bmcinfectdis.biomedcentral.com en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account